Loading organizations...
Thrivable provides a strategic patient insights platform designed to connect healthcare organizations with real-time patient experiences. The company develops a robust dataset of deeply profiled, engaged patients, enabling life sciences and healthcare entities to gain reliable and rapid insights into patient behaviors and preferences. Its AI-powered real-time insight engine allows decision-makers to move beyond traditional market research, offering continuous access to data that explains the 'why' behind patient actions.
David Edelman and Ryan Fuchs founded Thrivable in 2019, driven by the belief that patient perspectives should be more accessible and central to healthcare development. Edelman, who previously built the online community Diabetes Daily, envisioned a platform that would streamline patient input for product and service improvement. Fuchs, with a background in digital transformation consulting from Deloitte, brought expertise in scaling operations and customer experience strategy.
Thrivable serves a range of customers including pharmaceutical companies, medical technology firms, and contract research organizations, helping them make informed decisions based on comprehensive patient understanding. The company's vision is to bridge the existing gap between patient experience and healthcare innovation, fostering a future where continuous, reliable insights empower organizations to develop products and services that truly meet patient needs.
Thrivable has raised $8.0M across 2 funding rounds.
Thrivable has raised $8.0M in total across 2 funding rounds.
Thrivable is a healthcare technology company providing an on-demand, real-time market research platform that connects healthcare organizations with patients, primarily those with chronic conditions like diabetes, to generate rapid insights for decision-making.[1][2][3] It serves pharmaceutical, medtech, and healthcare agencies by enabling surveys, interviews, usability studies, clinical trial recruitment, and behavioral analysis through a panel of over 100,000 consented patients, delivering insights in hours rather than weeks.[1][3][6] The platform solves the challenge of accessing high-quality, real-time patient data to inform patient-centered strategies, market research, and product adoption, with over 1,000,000 insights generated to date and trusted fraud detection for reliability.[1][7]
Founded as Diabetes Daily in 2005 and rebranded to Thrivable around 2019, the company has raised $1.7M in funding (as of Feb 2024) from investors like JumpStart Ventures to expand its team in technology, research, sales, and marketing.[2][3][5] Headquartered in Bedford, Ohio, Thrivable demonstrates growth momentum through its expanding patient panel (from 40,000+ in 2024 to 100,000+), partnerships with top diabetes and obesity brands, and integration into workflows for faster pitches and validations.[1][3][6]
Thrivable originated as Diabetes Daily in 2005, initially focused on providing insights from diabetes patients and caregivers to inform healthcare strategies via a comprehensive database and platform.[3][5] By 2019, it evolved into Thrivable, broadening to a patient insights ecosystem for chronic conditions while retaining its diabetes expertise.[1][2] CEO David Edelman has led the company, emphasizing patient-centricity in competitive markets, with a pivotal $1.7M funding round in February 2024 from JumpStart Ventures' Evergreen Fund to scale operations.[2][3]
The idea emerged from the need for agile patient access in healthcare research, transforming slow traditional processes into on-demand tools. Early traction came from building a consented patient community (starting at 40,000+ by 2024, now over 100,000), generating 1M+ insights, and securing trust from leading pharma, medtech, and agencies through quality-assured data.[1][3][6]
Thrivable rides the wave of patient-centered healthcare innovation, where real-world evidence and behavioral insights are critical amid rising chronic disease prevalence (e.g., diabetes, obesity) and regulatory demands for patient voices in drug/device approval.[1][3][6] Timing aligns with post-pandemic acceleration in digital health tools, enabling pharma/medtech to achieve faster adoption/retention by understanding "why" behind patient behaviors, countering stagnant traditional research slowed by recruitment delays.[3][7]
Market forces favoring Thrivable include explosive growth in personalized medicine, AI-driven analytics needs, and competitive pressures for agility—patient-centric firms win, per CEO Edelman.[3] It influences the ecosystem by democratizing patient access for innovators, supporting U.S. market entry, and bridging gaps in claims data limitations, potentially shaping standards for rapid primary research in biotech conventions like BIO.[6]
Thrivable is poised to expand its panel and WhyRx capabilities, targeting global scaling post-2024 funding while deepening AI integrations for predictive insights amid booming obesity/diabetes markets.[3][6] Trends like value-based care and real-world data mandates will propel demand, evolving its role from research enabler to strategic partner in therapy optimization. As healthcare shifts to hyper-personalized, patient-led models, Thrivable's speed positions it to capture more share, reinforcing its foundation as the go-to for confident, voice-of-patient decisions.[1][7]
Thrivable has raised $8.0M in total across 2 funding rounds.
Thrivable's investors include Sixty8 Capital, Tamarind Hill, Lampros Capital Partners, LightShed Ventures, Primetime Partners.
Thrivable has raised $8.0M across 2 funding rounds. Most recently, it raised $6.0M Seed in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2023 | $6M Seed | — | Sixty8 Capital, Tamarind Hill | Announced |
| Jun 1, 2021 | $2M Seed | — | Lampros Capital Partners, Lightshed Ventures, Primetime Partners, Sixty8 Capital | Announced |
